Drug Trial Radar · NCT02146430
Treatment of Pain Associated With Fibromyalgia
Last checked: Nov 20, 2026Latest source record: Nov 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,293
Actual
Start
Oct 27, 2014
Primary completion
Jul 14, 2016
Study completion Jul 14, 2016
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- Syneos Health
- First posted
- May 23, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in subjects receiving either dose of DS-5565 versus placebo. Weekly ADPS is based on daily pain scores reported by the participant that best describes his or her worst pain over the previous 24 hours.
Conditions
- Pain Associated With Fibromyalgia
Interventions
DS-5565Drug
DS-5565 15 mg tablet for oral administration
PregabalinDrug
Pregabalin 150 mg capsule for oral administration
Placebo tabletDrug
Placebo tablet (matching DS-5565) for oral administration
Placebo capsuleDrug
Placebo capsule (matching pregabalin) for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Weekly Average Daily Pain Score (ADPS) at Week 13 in Participants Receiving DS-5565, Pregabalin, PlaceboTime frame: Baseline up to Week 13 postdose
Locations
165 sites in 11 countries. Site status is shown where the registry gives one.
Site not named
Glendale, Arizona
Site not named
Phoenix, Arizona
Site not named
Anaheim, California
Site not named
Beverly Hills, California
Site not named
Los Alamitos, California
Site not named
Newport Beach, California
Site not named
Oakland, California
Site not named
Rancho Mirage, California
Site not named
Roseville, California
Site not named
San Diego, California
Site not named
Sherman Oaks, California
Site not named
Torrance, California
Site not named
Tustin, California
Site not named
Colorado Springs, Colorado
Site not named
Denver, Colorado
Site not named
Cromwell, Connecticut
Site not named
Danbury, Connecticut
Site not named
Boynton Beach, Florida
Site not named
Bradenton, Florida
Site not named
Brooksville, Florida
Site not named
Coral Springs, Florida
Site not named
Gainesville, Florida
Site not named
Jacksonville, Florida
Site not named
Lakeland, Florida
Site not named
Miami, Florida
Site not named
Ocala, Florida
Site not named
Orlando, Florida
Site not named
Port Orange, Florida
Site not named
Royal Palm Beach, Florida
Site not named
Sanford, Florida
Site not named
St. Petersburg, Florida
Site not named
Savannah, Georgia
Site not named
Chicago, Illinois
Site not named
Elwood, Indiana
Site not named
Indianapolis, Indiana
Site not named
Newton, Kansas
Site not named
Wichita, Kansas
Site not named
Wheaton, Maryland
Site not named
Boston, Massachusetts
Site not named
Fall River, Massachusetts
Showing 40 of 165 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.